Literature DB >> 29198779

Mitotic rate is associated with positive lymph nodes in patients with thin melanomas.

Lee Wheless1, Chelsea A Isom2, Mary A Hooks2, Rondi M Kauffmann3.   

Abstract

BACKGROUND: The American Joint Commission on Cancer will remove mitotic rate from its staging guidelines in 2018.
OBJECTIVE: Using a large nationally representative cohort, we examined the association between mitotic rate and lymph node positivity among thin melanomas.
METHODS: A total of 149,273 thin melanomas in the National Cancer Database were examined for their association of high-risk features of mitotic rate, ulceration, and Breslow depth with lymph node status.
RESULTS: Among 17,204 patients with thin melanomas with data on Breslow depth, ulceration, and mitotic rate who underwent a lymph node biopsy, there was a strong linear relationship between odds of having a positive lymph node and mitotic rate (R2 = 0.96, P < .0001, β = 3.31). The odds of having a positive node increased by 19% with each 1-point increase in mitotic rate (odds ratio, 1.19; 95% confidence interval, 1.17-1.21). Cases with negative nodes had a mean mitotic rate of 1.54 plus or minus 2.07 mitoses/mm2 compared with 3.30 plus or minus 3.54 mitoses/mm2 for those with positive nodes (P < .0001). LIMITATIONS: The data collected do not allow for survival analyses.
CONCLUSIONS: Mitotic rate was strongly associated with the odds of having a positive lymph node and should continue to be reported on pathology reports.
Copyright © 2017 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  clinical research; guidelines; melanoma; mitotic rate; skin cancer; staging

Mesh:

Year:  2017        PMID: 29198779      PMCID: PMC6519988          DOI: 10.1016/j.jaad.2017.11.041

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  32 in total

1.  Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center.

Authors:  Manuela F Azzola; Helen M Shaw; John F Thompson; Seng-Jaw Soong; Richard A Scolyer; Geoffrey F Watson; Marjorie H Colman; Yuting Zhang
Journal:  Cancer       Date:  2003-03-15       Impact factor: 6.860

Review 2.  Prognostication in thin cutaneous melanomas.

Authors:  Phyllis A Gimotty; DuPont Guerry
Journal:  Arch Pathol Lab Med       Date:  2010-12       Impact factor: 5.534

3.  The prognostic importance of sentinel lymph node biopsy in thin melanoma.

Authors:  Jaime M Ranieri; Jeffrey D Wagner; Stacie Wenck; Cynthia S Johnson; John J Coleman
Journal:  Ann Surg Oncol       Date:  2006-05-22       Impact factor: 5.344

4.  Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas.

Authors:  Susan B Kesmodel; Giorgos C Karakousis; Jeffrey D Botbyl; Robert J Canter; Robert T Lewis; Peter M Wahl; Kyla P Terhune; Abass Alavi; David E Elder; Michael E Ming; DuPont Guerry; Phyllis A Gimotty; Douglas L Fraker; Brian J Czerniecki; Francis R Spitz
Journal:  Ann Surg Oncol       Date:  2005-04-19       Impact factor: 5.344

5.  Vertical growth phase and positive sentinel node in thin melanoma.

Authors:  R S Oliveira Filho; L M Ferreira; L J Biasi; M M S S Enokihara; G R Paiva; J Wagner
Journal:  Braz J Med Biol Res       Date:  2003-03-07       Impact factor: 2.590

6.  Results of sentinel lymph node biopsy in patients with thin melanoma.

Authors:  Sandra L Wong; Mary S Brady; Klaus J Busam; Daniel G Coit
Journal:  Ann Surg Oncol       Date:  2006-01-30       Impact factor: 5.344

7.  Identification of high-risk patients among those diagnosed with thin cutaneous melanomas.

Authors:  Phyllis A Gimotty; David E Elder; Douglas L Fraker; Jeffrey Botbyl; Kimberly Sellers; Rosalie Elenitsas; Michael E Ming; Lynn Schuchter; Francis R Spitz; Brian J Czerniecki; DuPont Guerry
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

8.  Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging.

Authors:  Phyllis A Gimotty; DuPont Guerry; Michael E Ming; Rosalie Elenitsas; Xiaowei Xu; Brian Czerniecki; Francis Spitz; Lynn Schuchter; David Elder
Journal:  J Clin Oncol       Date:  2004-08-09       Impact factor: 44.544

9.  Predictors of regional nodal disease in patients with thin melanomas.

Authors:  Giorgos C Karakousis; Phyllis A Gimotty; Jeffrey D Botbyl; Susan B Kesmodel; David E Elder; Rosalie Elenitsas; Michael E Ming; DuPont Guerry; Douglas L Fraker; Brian J Czerniecki; Francis R Spitz
Journal:  Ann Surg Oncol       Date:  2006-03-07       Impact factor: 5.344

10.  Final version of 2009 AJCC melanoma staging and classification.

Authors:  Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson; Michael B Atkins; David R Byrd; Antonio C Buzaid; Alistair J Cochran; Daniel G Coit; Shouluan Ding; Alexander M Eggermont; Keith T Flaherty; Phyllis A Gimotty; John M Kirkwood; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Arthur J Sober; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

View more
  6 in total

1.  Mitotic rate as an important prognostic factor in cutaneous malignant melanoma.

Authors:  A Piñero-Madrona; G Ruiz-Merino; P Cerezuela Fuentes; E Martínez-Barba; J N Rodríguez-López; J Cabezas-Herrera
Journal:  Clin Transl Oncol       Date:  2019-02-19       Impact factor: 3.405

2.  Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers.

Authors:  Clio Dessinioti; Niki Dimou; Alan C Geller; Aravella Stergiopoulou; Serigne Lo; Ulrike Keim; Jeffrey E Gershenwald; Lauren E Haydu; Simone Ribero; Pietro Quaglino; Susana Puig; Josep Malvehy; Lidija Kandolf-Sekulovic; Tatjana Radevic; Roland Kaufmann; Laura Meister; Eduardo Nagore; Victor Traves; Grigorios G Champsas; Mihaela Plaka; Brigitte Dreno; Emilie Varey; David Moreno Ramirez; Reinhard Dummer; Joanna Mangana; Axel Hauschild; Friederike Egberts; Ketty Peris; Laura Del Regno; Ana-Maria Forsea; Sabina A Zurac; Ricardo Vieira; Ana Brinca; Iris Zalaudek; Teresa Deinlein; Eleni Linos; Evangelos Evangelou; John F Thompson; Richard A Scolyer; Claus Garbe; Alexander J Stratigos
Journal:  J Natl Cancer Inst       Date:  2019-12-01       Impact factor: 13.506

3.  Survival analysis and sentinel lymph node status in thin cutaneous melanoma: A multicenter observational study.

Authors:  Antonio Tejera-Vaquerizo; Simone Ribero; Susana Puig; Aram Boada; Sabela Paradela; David Moreno-Ramírez; Javier Cañueto; Blanca de Unamuno; Ana Brinca; Miguel A Descalzo-Gallego; Simona Osella-Abate; Paola Cassoni; Cristina Carrera; Sergi Vidal-Sicart; Antoni Bennássar; Ramón Rull; Llucìa Alos; Celia Requena; Isidro Bolumar; Víctor Traves; Ángel Pla; A Fernández-Orland; Ane Jaka; María T Fernández-Figueres; Josep M Hilari; Pol Giménez-Xavier; Ricardo Vieira; Rafael Botella-Estrada; Concepción Román-Curto; Lara Ferrándiz; Nicolás Iglesias-Pena; Carlos Ferrándiz; Josep Malvehy; Pietro Quaglino; Eduardo Nagore
Journal:  Cancer Med       Date:  2019-06-18       Impact factor: 4.452

4.  Genotoxic potential of a novel PDE-4B inhibitor Apremilast by chromosomal aberration and micronucleus assay in mice.

Authors:  Muhammad Afzal; Imran Kazmi; Khalid Saad Alharbi; Anwarulabedin Mohsin Quazi; Muhammad Shahid Nadeem; Nasser Hadal Alotaibi; Nabil K Alruwaili; Firoz Anwar; Sattam Khulaif Alenezi; Mohammad M Al-Sanea
Journal:  Saudi Pharm J       Date:  2020-04-02       Impact factor: 4.330

Review 5.  Predictors of Nodal Metastasis in Cutaneous Head and Neck Cancers.

Authors:  Albert Y Han; Maie A St John
Journal:  Curr Oncol Rep       Date:  2022-04-08       Impact factor: 5.945

6.  Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis Prediction.

Authors:  Eric D Whitman; Vadim P Koshenkov; Brian R Gastman; Deri Lewis; Eddy C Hsueh; Ho Pak; Thomas P Trezona; Robert S Davidson; Michael McPhee; J Michael Guenther; Paul Toomey; Franz O Smith; Peter D Beitsch; James M Lewis; Andrew Ward; Shawn E Young; Parth K Shah; Ann P Quick; Brian J Martin; Olga Zolochevska; Kyle R Covington; Federico A Monzon; Matthew S Goldberg; Robert W Cook; Martin D Fleming; David M Hyams; John T Vetto
Journal:  JCO Precis Oncol       Date:  2021-09-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.